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The recentHIV-1 vaccine failures highlight the need to
better understand virus-host interactions. One key
question is why CD8+ T cell responses to two HIV-
Gag regionsareuniquely associatedwithdelayeddis-
ease progression only in patients expressing a few
rare HLA class I variants when these regions encode
epitopes presented by 30 more common HLA vari-
ants.Bycombiningepitopeprocessingandcomputa-
tional analyses of the two HIV subtypes responsible
for 60% of worldwide infections, we identified a
hitherto unrecognized adaptation to the antigen-pro-
cessing machinery through substitutions at subtype-
specific motifs. Multiple HLA variants presenting
epitopes situated next to a given subtype-specific
motif drive selection at this subtype-specific position,
and epitope abundances correlate inversely with the
HLA frequency distribution in affected populations.
This adaptation reflects the sum of intrapatient
adaptations, is predictable, facilitates viral subtype
diversification, and increases global HIV diversity.
Because low epitope abundance is associated with
infrequent andweak T cell responses, this most likely
results in both population-level immune evasion and
inadequate responses in most people vaccinated448 Cell Reports 7, 448–463, April 24, 2014 ª2014 The Authorswith natural HIV-1 sequence constructs. Our results
suggest that artificial sequencemodifications at sub-
type-specific positions in vitro could refocus and
reverse the poor immunogenicity of HIV proteins.INTRODUCTION
Because a safe and effective HIV-1 vaccine remains an elusive
goal, the basis for current vaccine strategies must be revisited.
Although the immune system never successfully clears HIV in
natural infection, the potential to contain the virus for decades
through cytotoxic T cell (CTL) responses has been demonstrated
in a minority of patients with rare human leukocyte antigen
(HLA) variants, particularly HLA-B*2705, -B*5701, -B*5703,
and -B*5801 (Goulder and Walker, 2012). The respective fre-
quencies of these HLA variants are 0%–14%, 0%–11%, 0%–
3%, and 0%–2% in whites and 0%–5%, 0%–6%, 0%–8%,
and 0%–14% in Africans (Gonzalez-Galarza et al., 2011). These
HLA molecules present key fragments (CD8 epitopes) of the
HIV-1 capsid protein p24 Gag on the surface of infected cells
to enable immune recognition and killing by CTL (Dahirel et al.,
2011; Dinges et al., 2010; Streeck et al., 2007). However, despite
progress (Elahi et al., 2011; Pereyra et al., 2010), the reason
these particular CTL responses are strongly linked to delayed
disease progression is not fully understood.
In addition to these protective CTL responses, there is an as-
sociation between CTL responses against p24 Gag and lower
mean viral loads in patients (Kiepiela et al., 2007). HLA-B rather
than the less diverse HLA-A or HLA-C restricts most of these re-
sponses although the underlying mechanism is unclear (Goulder
and Walker, 2012; Kiepiela et al., 2004). The current paradigm is
therefore that relatively few HLA variants are associated with re-
ductions in viral load and so impose a significant selective pres-
sure on HIV (Matthews et al., 2008).
Antigen processing is one crucial step in the pathway respon-
sible for HLA presentation of HIV epitopes to CTL. It is amultistep
process, where viral proteins synthesized in infected cells are
first degraded by cytosolic proteasomes. The proteasomes
appear in constitutive and interferon (IFN)-g-inducible immu-
noproteasomal forms; the latter is normally expressed in
lymphoid and antigen presenting cells but can be induced in
other cell types during HIV infection (Kloetzel, 2001; Tenzer
et al., 2004; Toes et al., 2001). Proteasomal cleavage products
(epitope precursors) might be further digested by cytosolic
peptidases before the transporter-associated-with-antigen-pro-
cessing (TAP) transfers them into the endoplasmatic reticulum
(ER). Here, they undergo N-terminal trimming by the ER amino-
peptidases (ERAP1,2) and are loaded onto any ‘‘restricting’’
HLA class I molecules with suitable anchors.
All CTL responses can select for mutations within or flanking
CD8 epitopes that allow HIV to escape CTL recognition. These
mutations may affect HLA binding, T cell receptor (TCR) con-
tact sites, and/or antigen processing (Draenert et al., 2004;
Goulder and Walker, 2012; Iversen et al., 2006; Tenzer et al.,
2009; Zhang et al., 2012). Escape mutations might confer
reduced viral fitness by coincidentally increasing epitope pro-
cessing (Tenzer et al., 2009) and/or reducing viral replication
or infectivity (Goulder and Walker, 2012). Such mutations
typically revert following transmission to HLA-mismatched
recipients (‘‘reverting mutations’’), whereas mutations with
no fitness cost persist (‘‘nonreverting mutations’’) (Matthews
et al., 2008).
The most effective CTL responses select for reverting escape
mutations (Matthews et al., 2008), and the accumulation of
these mutations at the viral population level due to factors
such as compensatory mutations might therefore affect HIV
control (Kawashima et al., 2009). Nonreverting escapemutations
are not associated with viral load reductions but might accu-
mulate and eventually replace the wild-type population. This
evasion of immune responses is so advantageous to HIV that
positive selection of escape mutations drives HIV evolution
within hosts (Rambaut et al., 2004).
Following HIV transmission, 35% of Gag substitutions in the
recipient is associated with HLA-mediated selection, and 70%
of these are reversions (Brumme et al., 2008). However, the
extent to which HIV evolves at the population level in response
to immune pressures is a matter of debate because of other in-
fluences, such as the founder effect (the random initiation of
epidemics in uninfected areas by a single or a few individuals’
HIV lineages), transmission bottlenecks that reduce genetic
diversity, and variation in the rates of partner exchange involving
sexual transmission. Bioinformatics studies have shown that
many polymorphisms in HIV are associated with particular host
HLA class I alleles (Bhattacharya et al., 2007); however, the
impact of these changes on antiviral immune responses is oftenunclear, and evolution among hosts is dominated by genetic
drift (Rambaut et al., 2004). Globally, HIV-1 forms geographically
distinct clusters, known as subtypes, which are labeled alpha-
betically. These subtypes are believed to be caused by founder
effects (Rambaut et al., 2004).
We and others have previously demonstrated that the
amount of epitopes made following in vitro proteasomal diges-
tions correlate with the magnitude and frequency of in vivo CTL
responses (Lazaro et al., 2009; Schmidt et al., 2012; Tenzer
et al., 2009), and studies have shown that epitope-specific
CTL recognition increases with increasing epitope production
and/or concentration (Almeida et al., 2007; Ranasinghe et al.,
2011; Zhang et al., 2012). Because of these correlations, HIV
sequence combinations that minimize or eliminate CD8 epitope
production through adaptation to conserved antigen-process-
ing preferences (Paulsson, 2004) would potentially be a very
efficient immune escape mechanism if they were to occur.
Here, we hypothesized that HIV adaptation to antigen-process-
ing preferences might limit CD8 epitope production at the viral
population level in a manner dependent on the HLA allele fre-
quency within a host population, thereby reflecting the sum of
all intrapatient adaptations and their transmissibility.
RESULTS
HIV CD8 Epitope Abundance Correlates Inversely with
Presenting HLA Frequencies in Infected Populations
To investigate the regulation of CD8 epitope production at the
viral population level, we studied the proteasomal processing
of HIV subtypes B (HIV B) and C (HIV C); HIV B predominates
in Western Europe and the US and accounts for approximately
11% of all infections worldwide, whereas HIV C prevails in
sub-Saharan Africa and is responsible for approximately 50%
of infections (Buonaguro et al., 2007). We focused on p24 Gag
and concentrated on the two conserved regions that dominate
the clinically effective HIV-specific CTL response in patients in-
fected by either HIV subtype (fragments 1 [F1] and 2 [F2], Fig-
ure 1A; Goulder and Walker, 2012).
The key p24 regions contain clusters of partially overlapping
CD8 epitopes, including the only four CD8 epitopes that are
strongly associated with delayed disease progression and 52
other epitopes that have no association with disease develop-
ment and are rarely recognized (Table S1) (Dinges et al., 2010;
Goulder and Walker, 2012; Streeck et al., 2007). Three of the
beneficial epitopes are presented by HLA-B*5701 and -B*5703
(15IW923, 30KF1140, and 108TW10117), and one is presented by
HLA-B*2705 (131KK10140); KF11 and TW10 may also be pre-
sented by HLA-B*5801 and -B*63, and IW9 is also presented
by HLA-A*25, -B*63, and -Cw*06 (Figure 1A; Table S1). KF11
also encodes a shorter epitope form, 30KI837 (Goulder et al.,
2000), presented by the same HLA variants. The nonprotective
epitopes are presented by 30 HLA class I variants, and, similar
to three of the protective epitopes, many can be presented pro-
miscuously by more than one HLA variant (Frahm et al., 2007).
These regions also contain five subtype-specific substitutions
that are situated either between or within the epitope clusters
(Figure 1A; [subtype B4C] 27V4I and 41S4T in F1; 116G4A,
120N4S, and 128E4D in F2).Cell Reports 7, 448–463, April 24, 2014 ª2014 The Authors 449
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To test the hypothesis that HIV adaptation to escape CTL re-
sponses may limit the production of viral epitopes in a manner
dependent on the HLA class I allelic frequency within a host pop-
ulation, we first generated proteasomal digestion data. We
designed overlapping HIV B and HIV C peptides (Figure 1B),
digested these with purified human constitutive proteasomes
and immunoproteasomes, and analyzed the resulting fragments
by mass spectrometry as in Tenzer et al. (2009).
Whereas proteasomal digestion produces the carboxyl
(C)-terminal end of most epitopes, several aminopeptidases in
the cytosol and the ER can trim the amino (N)-terminal peptide
extensions (van Endert, 2011). Therefore, we aligned the diges-
tion fragments with reported CD8 epitopes and defined an
epitope precursor as a peptide fragment that contained the cor-
rect C terminus of an epitope but could be extended by one or
several residues at the N terminus. Although most known CD8
epitopes are defined as ‘‘optimal epitopes,’’ i.e., the artificially
synthesized epitope-peptide form that elicits the greatest CTL
responses in vitro, we found that most epitopes were processed
as epitope precursors with N-terminal extensions (Table S1). For
each epitope, the intensities of the epitope precursor(s) and the
optimal epitope were combined for the calculation of the total
epitope production of a given epitope (‘‘epitope yield’’). Occa-
sionally, two or more epitopes, presented by different HLA class
I variants, shared the same C-terminal end but differed with
respect to the start of the N terminus; such epitope-precursor
fragments would be analyzed on their own.
We next used scatterplots to illustrate the relationship be-
tween HIV B or HIV C epitope yields and the HLA allelic fre-
quencies of epitope-presenting HLA variants in six white and
six sub-Saharan populations predominantly infected with HIV
B or HIV C, respectively (Figure 1C). If a given epitope-precursor
fragment contained a promiscuously presented epitope and/or
more than one epitope, we summed the frequencies of all HLA
variants that could present the epitope(s) encoded by that
epitope precursor. The abundance of epitope precursor frag-
ments containing the protective epitopes IW9, KF11/KI8, or
KK10 correlated with the summed frequencies of the presenting
HLA variants, whereas the production of TW10 was less than ex-
pected considering that the HLA-driven selective pressures on
TW10 and KF11 are similar (Figure 1C). However, TW10 differs
in two important respects from KF11: first, most of TW10 isFigure 1. Overview of the HIV p24 Gag Regions Analyzed
(A) Outline of p24 Gag fragment 1 (F1, amino acids 5–46, HIVHXB2 numbering) a
epitope clusters and subtype-specific positions (27, 41, 116, 120, and 128: orang
underlined; all epitopes are listed in Table S1.
(B) Outline of the overlapping 25-mer peptides used as proteasomal substrates u
into two parts (NF1 [N-terminal F1] and CF1 [C-terminal F1]), and F2 was divided
(C) Scatterplots of the relationship between the allelic frequency of a restricting
precursor is presented by more than one HLA molecule or if it contains more th
populations (infected primarily with HIV B or HIV C, respectively) and ‘‘epitope
represented as percentages of all peptide fragments) following 4 hr of immunopro
KF11 are grouped together as they are two forms of the same epitope. HLA res
variants signify epitopes that are not produced but are made following the proces
Asterisk, the HLA allelic frequency for the PY epitope is set at zero in HIV-B and H
2012; Sabbaj et al., 2003). The figure represents one of three independent exper
(D) Multilevel analysis with the three-way interaction of fragment (NF1, CF1, or MF
NF2 could not be analyzed due to differential epitope processing and restrictionincluded in epitopes presented by the common HLA-A*02
variant, and the combined selective pressures may further
reduce TW10 processing, and second, the cytoplasmatic pepti-
dase stability of TW10 (t1/2 = 31 min) is far greater than that of
KF11 (t1/2 = 13 s) and most other epitopes (Lazaro et al., 2011).
Because of this, the selective pressure to reduce the production
of TW10 might be stronger than for KF11.
Subsequently, we took within-population correlation into ac-
count by fitting a multilevel linear model to examine the influence
of the presenting HLA allelic frequencies, HIV region (NF1, CF1,
MF2&CF2), and ethnic group (Africans, whites) on epitope yield
(Table S2). This analysis demonstrated a significant three-way
interaction among fragment, HLA frequency, and ethnic group
on epitope yield. A strong relationship between epitope yield
and HLA allelic frequency was found for NF1, CF1 and
MF2&CF2 (Figure 1D), but, whereas similar variation in HLA fre-
quency had similar effects on epitope yields in NF1 and
MF2&CF2 regardless of ethnic group, a significant difference be-
tween ethnic groups was found with respect to CF1 (p < 0.0001).
As shown in the graph (Figure 1D, CF1), identical HLA-mediated
selection pressures in Africans and whites were typically associ-
ated with lower HIV C than HIV B epitope yields, especially at low
HLA allelic frequencies (p < 0.0001). Specifically, at anHLA allelic
frequency of 0.05 (equivalent to HLA variants found in 10%of the
population), the epitope yields from HIV C were only approxi-
mately 25% of those of HIV B (Figure 1D, CF1, dashed line).
The lower epitope yields might reflect a combination of a greater
adaptive potential of this region in HIV C, differences between
African and white HLA alleles, a bias in the database toward
HIV B epitopes, and/or the longer history of the HIV epidemic
in Africa. We next fitted the same model to epitope yields from
the constitutive proteasomal digestions and found similar pat-
terns (t test, p = 0.39–0.95) (Table S2).
As a result of theHLA-mediated adaptation of HIV to proteaso-
mal preferences, the CD8 epitopes presented by rare HLA vari-
ants are produced in greater quantities than those presented
either by common variants or by a combination of rare and com-
mon variants andmight therefore bemore likely to prime (Faroudi
et al., 2003) and/or be recognized by CTL (Purbhoo et al., 2004).
Collectively, our data provide compelling evidence that these
clinically important p24 HIV Gag regions adapt to proteasomal
preferences at the population level in response to selectionnd fragment 2 (F2, amino acids 100–143) that highlights the overlapping CTL
e boxes). The four epitopes presented by protective HLA class I molecules are
sing the HIV B and HIV C consensus sequences as examples. F1 was divided
into three parts (NF2, MF2 [Middle F2], and CF2).
HLA variant (or the sum of HLA variants if the CD8 epitope and/or epitope
an one epitope presented by different HLA variants) in six white and African
yield’’ (i.e., the abundance of individual epitopes and/or epitope precursors
teasomal digestion of either the consensus HIV B or HIV C sequence. KI8 and
triction details are shown in Table S1. Red epitopes and their restricting HLA
sing of either the other subtype or one of the sequence combinations (Table 1).
IV-C infection because of intraepitope CTL-escape mutations (Matthews et al.,
iments.
2&CF2), the presenting HLA allele frequency and ethnic group on epitope yield.
by only two HLA class I variants.
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pressures that are imposed by all epitope-restricting HLA class I
variants in an HLA frequency-dependent manner.
Processing Outcomes Are Supported by TAP Binding
and ERAP Trimming Preferences
To examine how TAP transport and ERAP trimming preferences
might affect the predicted epitope presentation and recognition
at the cell surface, we tested the subset of epitope precursors
with the protective IW9, KF11, KI, or TW10 motifs (Figure 2A).
To induce a CTL response, the epitope-precursor fragments
must first be transported by TAP into the ER, and, because
TAP transport rate is determined by binding, not translocation
(Gubler et al., 1998), we measured the normalized TAP affinities
of the precursors (Figure 2B). TAP binding affinity was sequence
but not length specific, given that TAP sometimes bound long
epitope precursors (>16 amino acids) better than shorter pep-
tides containing only parts of the longer sequence (e.g., AF19
versus VF14 and VF15, Figure 2B). Overall, most precursors
were transported well, especially those produced in the greatest
abundance (affinity <50).
Following TAP transport, epitope precursors associate with
HLA molecules, and the N-terminal part of the peptide may be
trimmed by ERAP before or after binding (van Endert, 2011).
We found that the longer epitope precursors were trimmed
more slowly. Furthermore, internal subtype-specific amino acid
differences could affect N-terminal trimming rates and thus
affect the repertoire of trimmed epitope-containing fragments
and the production of optimal epitopes (Figures 2C andS1). Spe-
cifically, the optimal TW10 epitope was observed only following
ERAP trimming of the RW18 precursor from HIV B, not HIV C,
because of a single amino acid variation at position 9 within
the epitope (position 17 within the 18-mer precursor, Figure 2C),
and the optimal KF11 epitope was undetectable due to rapid
degradation (Figure S1).
However, functional analyses of CD8+ T cell responses in four
untreated HIV-positive patients with HLA-B*5701 (Table S3)
demonstrated that the patients could recognize different
length variants of the same epitope and that recognition often re-
sulted in polyfunctional cytokine responses (Figure 2D). Taken
together, our TAP, ERAP, and CTL-recognition data suggest
that proteasomal digestion preferences often produce frag-
ments that accommodate TAP binding preferences, that most
epitope precursors are transported well into the ER, that a frac-
tion is trimmed to shorter epitope precursors and optimal
epitopes and that patients can recognize a variety of epitope-
peptide forms. Thus, the observed differences in proteasomal
epitope abundance appear to reflect differences in predicted
epitope abundances on the cell surface.Figure 2. TAP Binding, ERAP Trimming, and CD8+ T Cell Analyses
(A) Overview of the abundance of all IW9, KF11, KI8, and TW10 epitope forms p
(B) TAP binding affinity of the IW9, KF11, KI8, and TW10 epitope forms generated
and WF20, VI14, and VI12 were not tested. The epitope forms are colored as in
(C) ERAP1,2 digestion of the TW10 epitope precursor RW18 from HIV B and HIV
(D) PBMCs from four untreated HIV-1-infected patients with HLA-B*5701 (Table S
precursor peptides because of limited sample availability. IL-2, IFN-g, TNF-a, an
responding CD8+ T cells are shown after background subtraction, and each pept
the x axis, and the optimal epitope is shown in the top-left corner of the graph. TIntrahost HIV Adaptation to Antigen Processing
Decreases Epitope Production
Next, we investigated whether the inverse correlation between
the HIV B and HIV C CD8 epitope yields and the frequency
of the presenting HLA variants in the infected populations re-
flected the sum of individual adaptations within patients. To
investigate intrahost viral adaptation, we combined bioinformat-
ics analyses of HIV sequences from HLA-typed patients infected
with either HIV B or HIV C with processing analyses of 22
peptides containing all of the possible permutations of the
consensus sequences of the two subtypes (Figure 3). Each
variant differed by only one amino acid from the next, and,
whereas some substitution patterns were observed at a high fre-
quency in vivo, other patterns were rare (Table 1).
We used subtype-permutated peptides because sequence
variations in both p24 regions usually occur at the subtype-
specific positions (Figure S2) and because changes typically
occur to the preferred amino acid in the other subtype (Fig-
ure S3). In the minority of patients able to present the protective
IW9, KF11, TW10, or KK10 epitopes, additional variation could
sometimes be found at positions associated with well-described
CTL-escape mutations (e.g., 14A/P [IW9], 110T/N [TW10],
Table S4).
We compared variations in epitope-abundance for every
epitope in F1 and F2 with the specific amino acid that was
selected for at subtype-specific positions in HIV isolated from
patients with HLA variants able to present each epitope (Table
S4). The consensus HIV B (or HIV C) sequence was typically
observed in carriers of common HLA variants (e.g., HLA A*02,
HLA A*03, HLA B*07, and HLA B*44) and was the sequence
combination associated with the minimal generation of present-
able epitopes.
In contrast, in most HIV-B- or HIV-C-infected individuals with
rare HLA variants, we found one or more substitutions at sub-
type-specific positions that disrupted the HIV consensus
sequence. Because of these substitutions, the abundance of
the epitopes that these HLA variants could potentially present
was reduced relative to that found following the processing of
the consensus sequences. These substitution dynamics could
deviate within HLA suballeles; for example, in HIV-B-infected
patients with HLA-B*5701 or -B*5703, which present the same
three protective epitopes (IW9, KF11 and TW10), the selection
at subtype-specific positions either concurred (1/4; 41S/T) or
diverged (3/4; 27V/I, 116G/A, 120N/S; Table S4).
Divergent selection could result in quite large differences as,
e.g., 120S was found in over 80% of HIV B sequences from
patients with HLA-B*5701, but in none with HLA-B*5703 (Figures
4 and S4). As a result of these differences, the proteasomalroduced after 4 hr constitutive (c-p) or immunoproteasomal (i-p) digestion.
by proteasomal digestion. GW12 could not be tested because it was insoluble
(A). The results represent one of at least two independent experiments.
C. The result represents one of three independent experiments.
3) were stimulated with a subset of IW9, KF11, KI8, and TW10 HIV B epitope-
d CD107a responses were analyzed using flow cytometry. The percentages of
ide was tested two to three times. The epitope-peptide form is indicated along
he epitope forms made by the proteasome are colored as in (A) and (B).
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Figure 3. Epitope Production after Proteasomal Digestion of F1 and F2 Variants
(A) Overview of the NF1 andCF1 subtype-specificmotifs (orange boxes), the HIVB andHIV C consensus sequences, and all combinations of the subtype-specific
amino acids with a color-code key. The abundances of individual epitopes were represented as percentages of all peptide fragments following constitutive and
immunoproteasomal digestion, and the epitopes are shownwith the restricting HLA variants. RV9 and EV9were produced in amounts too small to be easily visible
in this figure. The results represent one of three independent experiments. F1 contains the protective epitopes IW9 (NF1) and KF11 (CF1) and overlapping
epitopes (Figure 1A, Table S1). Asterisk, QR10; arrow, QW11 (IW9); pin, KF11.
(B) As in (A) except that all F2 peptide variants are shown in Table 1. SM10, TT10, EN12, andWV10 were produced in amounts too small to be easily visible in this
figure. F2 contains the protective TW10 epitope (NF2) and several KK10 epitope forms (MF and CF2; in brackets) and overlapping epitopes (Table S1). Arrow,
TW10; pins, KK10 epitope forms.production of IW9 and TW10 will likely be lower in patients with
HLA B*5701 than in those with HLA B*5703, and the greater
epitope abundance in the latter group may lead to stronger
CTL responses and help to explain the higher frequency of
associated flanking and intraepitope CTL-escape mutations
in HIV from these patients (Table S4; 14A/P: HLA B*5701,454 Cell Reports 7, 448–463, April 24, 2014 ª2014 The Authors2%; HLA B*5703, 41%; 110T/N: HLA B*5701, 19%; HLA
B*5703, 41%).
Some epitope precursors contained overlapping epitopes
that were restricted by more than one HLA variant. One
example is the in vitro defined optimal KK10 epitope, which is
presented by the protective and rare HLA B*2705 molecule
Table 1. Frequencies of Subtype-Specific Amino Acid Combinations in HIV-B- and HIV-C-Infected Individuals and an Outline of the
Overlapping 25-mer Peptides Used as Proteasomal Substrates
Fragment Subtype Subtype-Specific Motif Amino Acid Sequence HIV B (%) HIV C (%)
NF1 B 27V NLQGQMVHQAISPRTLNAWVKVVEE 23 3
C 27I NLQGQMVHQAISPRTLNAWVKVIEE 8 35
CF1 B 27V, 41S AWVKVVEEKAFSPEVIPMFSALSEG 44 <1
27I, 41S AWVKVIEEKAFSPEVIPMFSALSEG 13 1
27V, 41T AWVKVVEEKAFSPEVIPMFTALSEG 11 6
C 27I, 41T AWVKVIEEKAFSPEVIPMFTALSEG 5 63
NF2 B 116G, 120N RGSDIAGTTSTLQEQIGWMTNNPPI 36 <1
116A, 120N RGSDIAGTTSTLQEQIAWMTNNPPI 5 4
116G, 120S RGSDIAGTTSTLQEQIGWMTSNPPI 10 1
C 116A, 120S RGSDIAGTTSTLQEQIAWMTSNPPI 1 14
MF2 B 116G, 120N, 128E IGWMTNNPPIPVGEIYKRWIILGLN 29 <1
116A, 120N, 128E IAWMTNNPPIPVGEIYKRWIILGLN 5 1
116G, 120S, 128E IGWMTSNPPIPVGEIYKRWIILGLN 8 <1
116G, 120N, 128D IGWMTNNPPIPVGDIYKRWIILGLN <1 <1
116A, 120S, 128E IAWMTSNPPIPVGEIYKRWIILGLN 1 3
116A, 120N, 128D IAWMTNNPPIPVGDIYKRWIILGLN <1 4
116G, 120S, 128D IGWMTSNPPIPVGDIYKRWIILGLN <1 <1
C 116A, 120S, 128D IAWMTSNPPIPVGDIYKRWIILGLN <1 16
CF2 B 120N, 128E TNNPPIPVGEIYKRWIILGLNKIVR 36 3
120S, 128E TSNPPIPVGEIYKRWIILGLNKIVR 12 5
120N, 128D TNNPPIPVGDIYKRWIILGLNKIVR 2 6
C 120S, 128D TSNPPIPVGDIYKRWIILGLNKIVR <1 22
The first p24 fragment was divided into two parts (NF1 and CF1), and the second was divided into three parts (NF2, MF2, and CF2). The underlined
amino acids are specific to HIV C.(whites, 0%–12%; absent in most African and Asian popula-
tions). This 10-mer epitope form is either processed in low
amounts or not at all, whereas the shorter or longer ‘‘KK10’’
epitope forms (KL8, KN9, KI11, KR13), which are also presented
by HLA B*2705, are produced in high abundance, primarily as
N-terminally extended epitope precursors (EL11 [KL8], EN12
[KN9], GI15 [KI11], KR13) and are associated with suboptimal
CTL responses (Tenzer et al., 2009) (Figure 3B; Table S1). These
epitope precursors contain overlapping epitopes that share the
same C terminus and can be presented by other, more common
HLA class I molecules and may encompass one embedded
epitope, PY9, presented by HLA-B*35 and -B*53; the only
epitope in this study that is surrounded by other epitopes (Fig-
ure 5A; Table S1). These epitope precursors were processed
with different efficiencies from HIV B and HIV C, and their abun-
dance was inversely correlated with the combined allelic fre-
quencies of the presenting HLA variants (Figures 1C and 3B,
MF and CF2, pins).
The cell-surface presentation of all epitopes encoded by these
‘‘KK10’’-containing epitope precursors may be modified by
other components of the antigen-processing machinery. More
specifically, the production of many of the optimal epitopes is
likely hampered because three proline (P) residues upstream of
most of these epitopes inhibit ERAP trimming (Figure 5B, accu-
mulation of KK10-containing trimming product with N-terminal
PP; Figure 5C, similar accumulation of an HLA B*8-restrictedGI8-containing trimming product with N-terminal NPP) and
because some precursors are cleaved by the cytosolic endo-
peptidase nardilysin (NRDc) (Kessler et al., 2011) (Figures 5A
and 5D; Table S1).
NRDc digestion selectively destroys the epitopes presented
by the common HLA-A*24 and -B*08 variants (Figure 5A),
whereas it releases all of the KK10 epitope forms together with
the internal PY9 epitope (Figure 5D). This PY9 production is un-
likely to affect CTL responses inmost patients because the HIV B
and HIV C consensus sequences each contain CTL-escape mu-
tations within PY9 that abolish the HLA-B*35-restricted CTL
response in HIV B infection, and the HLA-B*53-restricted CTL
response in HIV C (Matthews et al., 2012; Sabbaj et al., 2003).
The presence of these escape mutations at the subtype level
may reflect the benefit of a PY9-specific CTL response (Mat-
thews et al., 2012) and the opposing frequencies of these HLA
variants in whites and Central and Southern Africans (Gonza-
lez-Galarza et al., 2011).
Thus, overall intrahost selection can result in immune evasion
by favoring HIV sequence combinations that inhibit proteasomal
digestion and/or ERAP trimming and/or exploit NRDc to
decrease both overall and specific CD8 epitope presentation
and may also select for intraepitope CTL-escape mutations
that prevent epitope recognition. When we combined the
changes in specific epitope-precursor abundances and the
favored HIV selection within patients who shared the presentingCell Reports 7, 448–463, April 24, 2014 ª2014 The Authors 455
Figure 4. Intrahost Selection for the Subtype-Specific 120N/S
Substitution
Analyses of intrahost selection for the subtype-specificHIV 120N (HIVB)/ 120S
(HIV C) substitution in HIV-B- and HIV-C-infected subjects with HLA variants
restricting CD8 epitopes in F2 (all subtype-specific amino acid substitution
analyses are presented in Figure S4 and Table S4). The circles represent the
percentages of 120S in HIV from infected individuals who carry a specific HLA
variant (y axis: 120S+,HLAX+) and thepercentageof 120S in infected individuals
without this HLA variant (x axis: 120S +, HLA X). Therefore, the data illustrate
the extent to which a specific HLA variant is associated with HIV evolution at
position 120; specifically, circles above the line suggest positive selection,
circles on the line suggest no selection, and circles below the line suggest a
negative selection of 120S in patents with HLA X; Fisher’s exact test is used
to estimate significance and asterisks indicate that the two-tailed p value
is <0.05. Fewer than three HIV-B-infected patients carried HLA-B*63, and
an insufficient number of sequences were available from patients with
HLA-B*5801 and from HIV-C-infected patients with HLA-A*11, -B*53, -B*63,
and -B*27 to test for significance. The frequencies of 120S in HIV B and HIV C
from patients without HLA variants that could present epitopes from F2 were
6% and 72%, respectively.HLA variant, we found a strong, highly significant host-specific
bias toward residues that specifically decrease the yield of epi-
topes that the host could potentially target (Table S4, p <
0.0001 [HIV B] and p = 0.0005 [HIV C], sign test). Potentially
unrecognized CD8 epitope promiscuity will add noise to these
analyses, but does not compromise them. This result provides
strong evidence that all epitope-presenting HLA class I variants
exert a selective pressure on these clinically important HIV Gag
regions.
HLA-Driven Selection of HIV-C-like Subtype-Specific
Amino Acids in HIV B over Time in the Caribbean
To investigate how HLA-driven selection might impact HIV B
evolution over time, we studied longitudinal sequences from
five ethnically diverse populations (Figure 6A). The Caribbean
epidemic is particularly interesting because it is a unique
example of the spread of HIV B in populations that are primarily
of African ancestry. Specifically, 94/99 HIV B sequences (95%)
originated from Caribbean countries where >90% of the popula-
tion is black (Barbados, Haiti, and Jamaica). The region currently
has the second-highest HIV prevalence rate worldwide, but the
start of the epidemic within the region varies greatly; HIV B
appears to have spread from Africa to Haiti in approximately
1970 (Gilbert et al., 2007), to Jamaica in approximately 1987
(Losina et al., 2008), to Barbados in about 1990 (http://www.456 Cell Reports 7, 448–463, April 24, 2014 ª2014 The Authorsunaids.org), and to Trinidad and Tobago between 1993 and
1996 (Gilbert et al., 2007).
Despite the timing of the Caribbean epidemic, large numbers
of HIV B p24 sequences only became available after
2000 (http://www.hiv.lanl.gov/content/index). Subtype-specific
27V/I and 41S/T (‘‘HIV B consensus’’ or wild-type / ‘‘HIV-
C-like’’ or mutant) substitutions accumulated rapidly in HIV B
in the Caribbean cohort, reaching approximately 75% and
40%, respectively, after 5–10 years versus approximately
25%–35% (27I) and 10%–41% (41T), respectively, in the other
geographic regions (Figure 6A). At time period 3, this accu-
mulation was significantly greater than that found in all other
cohorts combined for 27V/I (p < 0.0001) but not for 41S/T
because of a comparable increase in the Asian cohort. More-
over, we observed parallel increases in HIV-C-like 116A (p =
0.05) and 120S frequencies (p = 0.05), whereas the HIV B wild-
type 128E/D substitution appeared less frequently, although
this difference did not reach significance. These observations
collectively provide evidence of distinct HIV B adaptation in the
Caribbean.
To investigate the underlying selective pressures, we exam-
ined the relationship between the frequencies of these HIV-C-
like substitutions in HIV-B-infected patients with and without
HLA variants that restrict epitopes in F1 and F2 (Table S4) and
the relative frequencies of these HLA variants in black Carib-
beans and whites (Figures 6B and S5) (Gonzalez-Galarza et al.,
2011). Because only HLA information from black Trinidadians
(BT) covered all of the necessary HLA variants, BT were used
to represent all the black Caribbeans, and all whites were repre-
sented by data for US whites (USW). These analyses revealed
which HLA variants select for HIV B wild-type amino acids and
which select for HIV-C-like amino acids, and if a given HLA
variant is more, or less, frequent in BT relative to USW; thus, Fig-
ures 6B and S5 illustrate the different, and similar, selective
forces in the two ethnic groups. We frequently observed
distinct HLA-associated selection pressures in each group. For
example, some HLA variants associated with selection of 120S
were underrepresented (HLA-A*24, B*07, and B*5701) in BT
when compared to USW (Figure 6B).
To examine the combined effect of the HLA-associated selec-
tive forces in each ethnic group, we summed the weighted allelic
frequencies of HLA variants selecting for HIV B wild-type or HIV-
C-like mutant amino acids at each of the five subtype-specific
positions for both BT and USW (Figure 6C). We then examined
whether the distribution of the sums was similar at each position
within and between the two populations (i.e., the distribution of
the light and dark orange [BT] and the light and dark blue
[USW] bar heights). Although we observed a similar distribution
between the sums of HLA alleles selecting for either mutant or
wild-type amino acids at positions 27 and 41 for both BT and
USW, we found a highly significant difference in the distribution
pattern between the two ethnic groups (p < 0.0001) (Table S5).
Similar strong ethnic differences were observed for the remain-
ing four positions (p < 0.0001 for each) combined with distinct
distribution patterns within the two populations when consid-
ering positions 116, 120, and 128 (p < 0.0001 for each).
For all positions, we next investigated whether the ratio of HLA
variants selecting for mutant over wild-type amino acids was
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Figure 5. Selective Production of the Internal PY9 Epitope and KK10 Epitope Variants
(A) Outline of the overlapping epitope region comprising the B27-KK10 epitope; prolines 122, 123, and 125 are underlined, the internal B35/53-PY epitope is
shaded red, and the cytoplasmic nardilysin (NRDc) recognition motif 131KR132 is gray (Kessler et al., 2011). Epitopes are boxed and HLA restriction elements are
displayed in the same color as the box. Arrow, NRDc cut site.
(B) ERAP1,2 digestion of the HLA-A*02, -A*03, -A*11, -A*33, and -B*2705-restricted GI15 precursor epitope. The result represents one of three independent
experiments.
(C) ERAP1,2 digestion of the HLA-B*08-restricted GI8 precursor epitope. The result represents one of three independent experiments.
(D) Outline of all proteasomal digestion fragments with different KK10 epitope forms produced following 4 hr of immunoproteasomal digestion of HIV B F2. The
position of prolines 122, 123, and 125 and the NRDc cut site are indicated; production of the internal PY9 epitope and the KK10 epitope forms are delineated. HLA
restriction elements are displayed next to the epitope precursors using the same color as in Figure 5A.different between BT and USW (Figure 6D). We found highly sig-
nificant differences in odds ratios between the two ethnic groups
(Table S5), which provides evidence of distinct HLA-mediated
selective pressure on HIV in each population.
Our results demonstrate that increases in the 27I, 41T, and 120S
HIV-C-like amino acids in HIV-B-infected BT are associated with
a higher prevalence ratio of HLA variants that select for these
amino acids relative to those selecting for the wild-type amino
acids 27V, 41S, and 120N compared with USW (Figure 6D). How-
ever, this finding did not reflect a higher relative abundance of
HLA variants that select for HIV-C-like amino acids, but rather,
a relative decrease of HLA variants that select for wild-type
amino acids at these positions in BT relative to USW because
the proportion of HLA variants selecting for wild-type amino
acids in BT relative to USWwas 0.65, 0.81, and 0.60 for positions
27, 41, and 120, respectively (Figure 6C; Table S5).
Similarly, the slight increase in the HIV B wild-type 128E
among BT was associated with a decrease in the frequency of
HLA variants selecting for the HIV-C-like 128D substitution,
because the proportion for USW was 1.6 times larger than the
proportion for BT (Table S5). The small increase in 116A over
time is an anomaly because the proportion for USW was 1.8
times that of BT, but this increase is likely due to strong
competing selective pressures affecting infectivity and natural
killer cell recognition, which have distinct effects on HIV B evo-lution in the two ethnic groups (Fadda et al., 2011; Martinez-
Picado et al., 2006).
When we examined how the USW and BT ratios of HLA vari-
ants that select for mutant over wild-type amino acids affected
substitution patterns at subtype-specific positions, we found a
highly significant positive correlation between these HLA ratios
and the frequency of the HIV-C-like 27I, 41T, 120S, and 128D sub-
stitutions in HIV-B-infected individuals from North America and
the Caribbean (Figure 6E, p = 0.0001). Position 116 was omitted
from this analysis due to the competing selective pressures.
Because the HLA ratio variation affected HIV B evolution at the
viral population level in a similar manner at all four subtype-spe-
cific positions in both ethnic groups, this ratio is the key driver of
HIV adaptation at these subtype-specific motifs.
This correlation directly links the distinct HIV B evolutionary
patterns to differences in the HLA haplotype distribution in the
two populations because the HLA data are not linked to the
acquisition of the HIV sequences. Because of this relationship,
our data provide compelling evidence that the specific amino
acid at a given subtype-specific position in HIV B Gag affects
the processing of all CD8 epitopes in nearby epitope clusters
and that viral evolution is influenced by the frequencies of all
HLA variants that can present CD8 epitopes from these clusters.
Together, our data strongly suggest that the combined effect of
these HLA-driven selective pressures on viral evolution isCell Reports 7, 448–463, April 24, 2014 ª2014 The Authors 457
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predictable and that viral founder effects are overlaid by rapid
adaptation to local HLA population frequencies.
Collectively, our data strongly suggest that the HIV B Gag-
consensus sequence is selected mainly by white HLA allelic
frequencies and that the ancestral African HLA distribution in
the Caribbean has shaped recent HIV B evolution in this location
in a manner similar to the manner in which the HLA profile of
infected sub-Saharan populations may have affected HIV C
evolution.
HLA-Driven Selection of Amino Acids in Subtype-
Specific Positions in HIV B across Populations
We next studied the influence of HLA frequency differences
on HIV B evolution across populations worldwide. The 120N
(HIV B)4 120S (HIV C like) interchange is particularly informative
because 120S simultaneously decreases B57-TW10 processing
and increases B27-KK10 production and because both epitopes
are associated with clinically beneficial CTL responses (Table
S4). We correlated HLA-B*2705 frequencies with the corre-
sponding HIV 120S and 120N frequencies and found a strong
inverse correlation between the HLA B*2705 and 120S HIV fre-
quencies (p < 0.0001), which was mirrored by a positive correla-
tion between HLA-B*2705 and 120N (p = 0.01) (Figure 6E). In
contrast, a trend toward a positive correlation was observed
for the HLA B*5701 and 120S frequencies despite the small size
and restricted range of the data set, resulting from the absence
of this HLA variant in most populations (n = 8, p = 0.18). The rarity
of HLA B*5701 made it difficult to estimate any impact on 120N
frequencies because 120N is positively selected in most HIV-B-
infected individuals (p = 0.24). Together, the correlation between
HLA frequencies across populations and the corresponding
selection for evasive substitutions in the circulating virus argue
strongly for the immune selection of HIV and viral adaptation to
antigen-processing preferences.
DISCUSSION
Here, we present an extensive study of HIV evolution and the
effect of HIV subtype-specific substitutions on proteasomal pro-Figure 6. HIV B Adaptation to the HLA Profiles of Host Populations
(A) One sequence from each HIV-B-infected patient was selected from the HIV d
amino acids in HIV Bwere calculated across the data set at the indicated time peri
Caribbean, 160, 575, and 556; Europe, 69, 254, and 375; Caribbean, 2, 68, and 31
114, and 44. Fisher’s exact test was used to compare mutation frequencies at
combined (*p < 0.05, ***p < 0.0001).
(B) The frequency of an HLA variant in black Trinidadians (BT)/US whites (USW) ve
HLA variant is illustrated using log scales (all analyses, Figure S5 and Table S4).
(C) The summed allelic frequencies of HLA variants selecting for HIV B wild-type
the five subtype-specific positions for BT and USW; p values for the ethnic diff
(***p < 0.0001) (Table S5).
(D) The ratios of the summed weighted HLA allelic frequencies in BT and USW tha
(Table S4; Table S5; Figure S5).
(E) A binomial GLM produced the graph of the frequency of p24 Gag 27I, 41T, 120S
ratios of the summed HLA allelic frequencies in BT or USW that select for M/W
because of competing selective pressures.
(F) HLA-B*2705 frequencies versus the frequencies of HIV B p24 Gag 120N and 12
was obtained by fitting a binomial GLM to the points. n = number of sequences, A
(n = 68); CN, China (n = 75); CO, Columbia (n = 7); DE, Germany (n = 14); DK, Denm
HT, Haiti (n = 16); JM, Jamaica (n = 14); JP, Japan (n = 27); KR, Korea (n = 18); Tcessing ofmore than 50 epitopes presented by approximately 30
HLA class I variants in two key clinically relevant HIV B and HIV C
Gag regions. We have identified a hitherto unrecognized adapta-
tion of HIV Gag to the antigen-processing machinery at the viral
population level. This adaptation occurs through substitutions at
subtype-specific motifs, and multiple HLA variants presenting
nearby epitopes all drive selection at the same subtype-specific
position.
We provide evidence of a three-way interaction among HIV re-
gion, HLA frequency, and ethnic group and demonstrate that the
proteasomal processing of all CD8 epitope precursors inversely
correlates with the HLA allelic frequency of the presenting HLA
variant(s) in the infected populations. Because of this adaptive
process, epitopespresentedbycommonHLAvariants aregener-
ated in low amounts, whereas epitopes presented by rare HLA
variants are made in abundance. Taken together with the re-
portedweakand infrequentCTL responsesassociatedwith com-
mon HLA variants, and the strong and frequent CTL responses
associated with rare HLA variants in these Gag regions (Goulder
and Walker, 2012; Streeck et al., 2007), our results support
previous findings linking epitope-abundance to the magnitude
and frequency of epitope-specific CTL responses (Lazaro et al.,
2009; Ranasinghe et al., 2011; Schmidt et al., 2012; Tenzer
et al., 2009). Our data provide clear evidence that all epitope-
presenting HLA class I variants exert selective pressures on sub-
type-specific positions in these key HIV Gag regions, resulting
in population-level immune evasion in both HIV B and HIV C
infection.
We demonstrate that this population-level immune evasion re-
flects the sum of intrapatient adaptations to reduce or obliterate
the production of potentially presentable CD8 epitopes. Specif-
ically, we show that the prevailing amino acid in either the HIV B
or HIV C consensus sequence is associated with the least
production of the epitopes presented by the most common
HLA variants in both the HIV-B- and HIV-C-infected populations.
In contrast, in patients with relatively rare HLA variants, HIV was
often found to have nonconsensus amino acids at subtype-spe-
cific positions that were associated with a reduction in process-
ing of the epitope presented by these rare HLA variants.atabase. The frequencies of HIV-C-like p24 Gag 27I, 41T, 116A, 120S, and 128D
ods in five geographic regions (region, n from time periods 1, 2, and 3), all minus
; Asia, 27, 96, and 97; North America, 47, 111, and 40; and South America, 17,
time period 3 between sequences from the Caribbean and all other cohorts
rsus the HIV B 120N/S substitution frequencies in subjects with or without that
(‘‘WT’’) and HIV-C-like amino acids (‘‘Mutant’’ or ‘‘M’’), respectively, at each of
erences were calculated by fitting a binomial generalized linear model (GLM)
t select for M/WT amino acids at each subtype-specific position (***p < 0.0001)
, and 128D in HIV B sequences from the Caribbean or North America versus the
T amino acids at each subtype-specific position. Position 116 was excluded
0S in sequences from each country during 2000–2009. The superposed curve
R, Argentina (n = 78); AU, Australia (n = 21); BB, Barbados (n = 64); BR, Brazil
ark (n = 23); ES, Spain (n = 8); FR, France (n = 7); GB, United Kingdom (n = 526);
H, Thailand (n = 17); and US, USA (n = 122).
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Thus, the HIV consensus sequences might be perceived as
the best HIV sequence for immune evasion in the majority of in-
fected individuals in whom additional individual HIV adaptations
to escape the antiviral immune response take place. These indi-
vidual adaptations may include intraepitope CTL escape muta-
tions that affect, e.g., HLA binding or TCR recognition and/or
further adaptations to limit antigen processing (Goulder and
Walker, 2012). Notably, these individual adaptations typically
differ from the HIV B or HIV C consensus sequence, which sug-
gests that most of these substitutions impose fitness costs on
HIV that select for reversion upon transmission to an HLA-
mismatched recipient. Therefore, this process is very different
from the adaptive process we describe here, which helps to
create and/or modify HIV subtypes through adaptations to pro-
teasomal preferences at subtype-specific motifs. This HLA-fre-
quency-driven process is so advantageous to viral survival and
transmission that it largely shapes the HIV B and HIV C Gag
consensus sequence.
This process of adaptation to all HLA-A, -B, and -C variants
may also help to explain the generally better control of HIV repli-
cation by HLA-B-restricted CTL responses (Kiepiela et al., 2004).
HLA-B has more alleles (2,068) than either HLA-A (1,518) or
HLA-C (1,016) (Gonzalez-Galarza et al., 2011); the HLA-B locus
has the highest occurrence of heterozygosity because of a
more even distribution of allele frequencies (Cao et al., 2001);
and HLA-B variants bind an even greater variety of peptides
(Marsh et al., 2000). As a result, the selective pressures on
each peptide:HLA B combination may be lower, and this will
lead to slower adaptation. Hence, we hypothesize that HLA-B-
restricted epitopes are likely to be produced in higher amounts
than those restricted by HLA-A and HLA-C, and this higher
epitope abundance is likely to result in a more frequent priming
of CD8+ T cells and more efficient elimination of infected cells
(Faroudi et al., 2003). Thus, it is likely due to the generally
reduced selective pressure by HLA-B to limit or obliterate CD8
epitope production that HLA-B-restricted CTL responses domi-
nate the CTL response against HIV.
Our study of HIV evolution over time in five ethnically diverse
populations perhaps most clearly demonstrates the broader
importance of the correlation betweenHLA and subtype-specific
polymorphisms in HIV Gag. We observed that HIV B in the black
Caribbean population evolved in a manner resembling that of
HIV C in Central and Southern Africa and that this pattern was
associated with a relative decrease of HLA variants selecting
for HIV B consensus amino acids when compared with whites
in the US. Moreover, we found evidence of a worldwide adapta-
tion of HIV B to the HLA-B*2705 allelic frequency in infected
populations, providing evidence of adaptation both between
and within ethnic groups. Thus, HIV Gag subtypes have diver-
sified in part because of their adaptation to the local HLA allelic
frequency distributions, which contrasts with the current para-
digm that HIV subtype diversification is mainly due to random
founder effects (Rambaut et al., 2004). Although founder effects
likely also contribute, our data provide strong evidence that
founder effects are followed by the rapid adaptation to local
HLA population frequencies in a predictable manner. This rapid
adaptation may not have been observed previously because of
insufficient sequence data from most countries during the start460 Cell Reports 7, 448–463, April 24, 2014 ª2014 The Authorsof the epidemic and a lack of data relating to antigen processing
of HIV.
Our data should be interpreted cautiously when considering
other HIV proteins because the extent of HIV adaptation to anti-
gen processing will likely depend on the strength of the selective
pressure exerted by CTL responses and because discordant
associations exist between viral load and CTL responses toward
different HIV proteins (Kiepiela et al., 2007). Vulnerable regions
within other HIV proteins may also demonstrate variable adapta-
tion to the same HLA selective pressure, in line with the different
HIV B and HIV C CF1 epitope yields. The Gag regions we
analyzed in this study are the only regions in the HIV proteome
where CTL responses are strongly associated with delayed dis-
ease progression (Goulder andWalker, 2012), and these regions
are therefore potentially important to target through vaccination.
Our data provide compelling evidence that differences in epitope
abundance are part of the reason these two key p24 regions only
elicit strong and frequent CTL responses in the minority of
patients with a few rare HLA-B variants.
Although the high evolutionary rate of HIV makes it possible to
study the ongoing coevolution of HIV and the host immune
response, any pathogen that is largely controlled by CTL re-
sponses might similarly adapt to the human antigen-processing
machinery to limit epitope production. Differences in HLA fre-
quencies between populations are thought to reflect differences
in infectious challenges; however, it is likely that the distinct HLA
profiles in different populations also impact the evolution of
pathogens other than HIV. Possible candidates may include
pathogens largely controlled by the CTL response that have
long coexisted with humans and have diversified into subgroups
in distinct geographic regions such as hepatitis B virus and hep-
atitis C virus.
Because HIV-1 selectively adapts to the HLA distribution of
the infected population, vaccines based on locally prevalent
HIV sequences would be predicted to result in weaker and less
frequent CD8+ T cell responses than vaccines containing a
mosaic of subtypes or ancestral or consensus HIV sequences in-
ferred from patient-derived virus. However, all these naturally
selected HIV sequences will likely result in weak CD8+ T cell re-
sponses in themajority of vaccinated HIV-uninfected individuals,
regardless of how they are chosen and combined, due to similar-
ities among HLA frequencies in different ethnic groups (Cao
et al., 2001). Therefore, even the creation of mosaic HIV inserts
based on natural HIV sequences is unlikely to substantially in-
crease the processing of epitopes presented by most of the
common HLA variants.
We demonstrate that viral evolution in vivo can alter the pro-
cessing of all epitopes in overlapping epitope clusters through
substitutions at subtype-specific motifs, which suggests that
artificial sequence modifications at these positions in vitro could
refocus and reverse the poor immunogenicity of HIV proteins.
This vaccine concept would exploit the fact that CD8+ T cells
have two distinct antigen-load-dependent activation thresholds:
one for clonal expansion and one for target cell elimination (Far-
oudi et al., 2003). Processing of a modified insert might generate
epitopes in high abundance that will elicit strong CTL responses
capable of eliminating naturally infected cells that display as little
as three peptide:HLA complexes on their surface (Purbhoo et al.,
2004). Thus, vaccine efficacy might be improved by unnatural
substitutions that increase the processing of subdominant CD8
epitopes presented by common HLA variants in vulnerable parts
of the virus.
EXPERIMENTAL PROCEDURES
Patients and HLA Typing
Chronically HIV-1-infected patients were recruited from the Department of
Infectious Diseases, Rigshospitalet, Denmark (Table S3). All patients gave
informed consent and were studied according to the regulations of the Danish
Board of Medical Ethics for human experiments. HLA genotyping was done
using multiplex PCR (Dynal Biotech).
Peptide Synthesis and Purification
Peptides were synthesized on an MK-IV peptide synthesizer (Schafer-N) and
purified to >98% purity using a JupiterProteo C12 column (Phenomenex) as
in Tenzer et al. (2009).
Purification of Proteasomes and In Vitro Digestions
Constitutive proteasomes and immunoproteasomes (20S) were purified from
LCL721.174 and LCL721 EBV-transformed human B cell lines as in Tenzer
et al. (2004). We performed 2, 4, and 6 hr digestions with purified constitutive
proteasomes and immune proteasomes (substrate:enzyme ratio:1,000:1); all
peptide digests in one experimental set were performed on the same day.
We used the 4 hr digestion results here to allow detection of all cleavage
products while minimizing effects of proteasomal re-entry of already digested
peptide as less than 40% of the initial substrate was degraded at this time in all
experiments.
Analysis of Peptide Digests by Mass Spectrometry
We performed capillary liquid chromatography of all peptide digests using a
Waters NanoAcquity UPLC system and mass spectrometry analysis as in
Tenzer et al. (2009) and the Supplemental Experimental Procedures. Each
sample was analyzed in triplicate. We used the ProteinLynx Global Server
version 2.2 for the processing, identification and quantification of the LC-
MSE data. The mass error tolerance values were typically <5 ppm. We used
mass spectrometric fragment intensity as a surrogate marker for quantity
because we previously found a highly significant correlation between these
two parameters (Tenzer et al., 2009).
TAP-Peptide Binding Assays
The TAP-peptide binding of epitope precursors and optimal epitopes was
determined as in Tenzer et al. (2009) and the Supplemental Experimental
Procedures.
In Vitro Peptide Digestions with ERAP Enzymes
Each peptide was incubated with human ERAP1/2 complexes as in Tenzer
et al. (2009) and the Supplemental Experimental Procedures. Aliquots were
removed for analysis at the indicated time points.
Intracytoplasmic Cytokine Staining
About 150,000 peripheral blood mononuclear cells (PBMCs) per well were
stimulated in a 96-well plate with peptides (2.5 ng/ml), 1 mg/ml anti-CD28,
anti-CD49d, and anti-CD107a FITC (BioLegend) for 6 hr. After 30 min,
5 mg/ml Brefeldin A and 13 Monensin (BioLegend) were added. The positive
control contained 2.5 ng/ml PMA and 25 ng/ml ionomycin, and the negative
cells and CD28/CD49d. Cells were washed and stained with LIVE/DEAD
Fixable Violet stain (Invitrogen), fixed, and permeabilized with BD Fix/Perm
solution (BD) and stained with a mix of fluorochrome-conjugated antibodies:
CD3 EDC, CD8 PerCP (BD), interleukin (IL)-2 PE, IFN-g, Pe-Cy7, and tumor
necrosis factor (TNF)-a APC (BioLegend). Unstained and singly stained cells
were used as controls to calculate compensation. The cell fluorescence inten-
sities were acquired on a Cyan ADP Cytometer (Beckman Coulter) and
analyzed with Summit software (Dako).Sequence Analyses
All sequences were obtained from the HIV database (http://www.hiv.lanl.gov/
content/index). We grouped HIV B and HIV C sequences from 1980 to 2009
according to (1) 5 year time period and (2) 5 year period and geographic region.
Group 3 consisted of all HIV B sequences from 2000 to 2009 grouped accord-
ing to geographic region, and group 4 contained all sequences from HLA-
typed HIV-B- or HIV-C-infected persons divided according to HLA group;
this group was further divided into groups of patients with or without specific
HLA variants (Table S4). We used the sequence tool in the HIV database to
randomly select only one sequence from each patient or transmission cluster
in groups 1–3 to avoid skewing. We excluded sequences with translational
problems (i.e., frameshift or stop codons).
Shannon Entropy analyses (http://www.hiv.lanl.gov/content/index) were
done on sequence set 1. Sequence changes in geographic regions over
time were examined using set 2. HIV adaptation in specific countries was esti-
mated using set 3. Differences in amino acid frequencies in HIV Gag from
patients with or without specific HLA alleles were estimated using set 4. We
counted and calculated the amino acid frequencies at each HIV-1 Gag p24
position; each query HIV-1 gag sequence was pairwise aligned to the HXB2
reference strain and mutations were defined as changes relative to this
sequence. The frequency of mutations in the p24 gene was then calculated
across each of the data sets 2–4. Because we analyzed all HIV sequences in
the database, our intraepitope mutation frequencies (Table S4) might differ
from those reported by smaller cohorts. The HIV-1 consensus sequences
were obtained from the HIV database.
Epitope Designation and HLA Analyses
HLA allelic frequencies were obtained from the Allele Frequency Database
(Gonzalez-Galarza et al., 2011) and (Assane et al., 2010; Novitsky et al.,
2001). When more than one data set was available from a country, we used
weightedmean values unless otherwise specified. For the analyses in Figure 1,
we used HLA frequencies from the UK (UK1 = Leeds [n = 5,024], UK2 = Shef-
field [n = 4,755]), the US (US1 = Los Angeles, Seattle, and Detroit [n = 1,070],
US2=Bethesda [n = 307]), Germany (n = 11,407), France (n = 130), South Africa
(Zulu, n = 100; Xhosa, n = 50), Zambia (n = 256), Zimbabwe (n = 108), Botswana
(n = 161), and Mozambique (n = 250). We labeled peptide fragments as CD8
epitopes based on the HIV immunology database (http://www.hiv.lanl.gov/
content/immunology). Because studies disagree as to whether HLA-Cw*03
can bind the VL10 epitope (Zappacosta et al., 1997; Zarling and Lee, 1998),
we did not include a selection pressure from HLA-Cw*03 in our analyses.
Statistical Analyses
We used multilevel modeling to examine the effects of HLA frequency, HIV
region, and ethnic group on epitope yield. Further analyses were done using
binomial generalized linearmodels (McCullough andNelder, 1989) using the ca-
nonical logit link function, Fisher’s exact test, t tests, and a nonparametric sign
test as described in the text and in the Supplemental Experimental Procedures.
These analyseswere done usingGraphPadPrism5 (GraphPad), theR statistical
package (version 3.0.0 [2013-04-03]),Microsoft Excel 2007 (Microsoft), andStat
Trek (Stattrek.com) software. A value of p < 0.05 was considered significant.
Graphs were made using GraphPad Prism 5, R, and Microsoft Excel 2007.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.03.031.
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